High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement

Internal Medicine

Volumn 44, Issue 5, 2005, Pages 484-489

  Shimojima, Yasuhiro ^a   Matsuda, Masayuki ^a   Ishii, Wataru ^a   Koyama, Jun ^a   Yamamoto, Kanji ^a   Shimodaira, Shigetaka ^a   Sakashita, Kazuo ^a   Koike, Kenichi ^a   Ikeda, Shi Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AL amyloidosis; Autologous peripheral blood stem cell transplantation; Free light chain; High dose melphalan; Natriuretic peptide; VAD

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; AMYLOID PROTEIN; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CIPROFLOXACIN; CREATININE; DEXAMETHASONE; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; MELPHALAN; PROTON PUMP INHIBITOR; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AMYLOIDOSIS; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CARPAL TUNNEL SYNDROME; CASE REPORT; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DRUG MEGADOSE; DYSESTHESIA; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INFECTION PREVENTION; INTESTINE OBSTRUCTION; LUNG EDEMA; MACROGLOSSIA; MALE; MULTIPLE ORGAN FAILURE; PNEUMONIA; PROTEIN BLOOD LEVEL; PROTEINURIA;

AMYLOID; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOPSY, NEEDLE; BONE MARROW; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SUBMANDIBULAR GLAND; TIME FACTORS; TONGUE; TRANSPLANTATION, AUTOLOGOUS;

EID: 21244485445     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.484     Document Type: Article

References (24)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995.
2. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99: 4276-4282, 2002.
3. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med 91: 141-157, 1998.
4. Iggo N, Littlewood T, Winearls CG. Prospects for effective treatment of AL amyloidosis? Q J Med 93: 257-260, 2000.
5. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid lightchain) amyloidosis: survival and responses in 25 patients. Blood 91: 3662-3670, 1998.
6. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103: 3960-3963, 2004.
7. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for management of primary systemic amyloidosis. Am J Med 113: 549-555, 2002.
8. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19: 3350-3356, 2001.
9. Blum W, Khoury H, Lin HS, et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant 9: 397-404, 2003.
10. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444, 2002.
11. Witzenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 103: 468-473, 1982.
12. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101: 766-769, 1998.
13. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 33: 271-277, 2004.
14. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26: 963-969, 2000.
15. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese criteria for patient selection and our experiences. Amyloid: J Protein Folding Disord 11: 245-256, 2004.
16. Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16: 1135-1141, 1990.
17. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107: 2446-2452, 2003.
18. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 31: 754-765, 1998.
19. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107: 2440-2445, 2003.
20. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 24: 853-855, 1999.
21. Stevens JM, Patton VVN, Heaton DC, et al. Autologous PBSCT in patients with cardiac amyloidosis. Bone Marrow Transplant 26: 588-589, 2000.
22. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444, 2002.
23. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119: 274-278, 2003.
24. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 2003.